Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04265170 · ClinicalTrials.gov registry record · NA
Evaluating Blast-X® in Combination With Negative Pressure Wound Therapy
A NA study of Pressure Ulcer, sponsored by SerenaGroup.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04265170: Completed NA study of Pressure Ulcer, sponsored by SerenaGroup.
NCT04265170 is a NA study of Pressure Ulcer that has completed, run by SerenaGroup. The registered enrollment target is 20 participants, below the 30,115-participant average among 10 other Pressure Ulcer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04265170, a NA study of Pressure Ulcer, has completed, sponsored by SerenaGroup.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A Multi-center, Prospective Clinical Trial Evaluating the Combination of BlastX and Negative Pressure Wound Therapy (VAC).To evaluate the 4-week healing trajectory/wound area reduction with BlastX/VAC as compared with historical pre-study 4-week healing trajectory data and data from the US Wound Registry.
Primary Outcome
The number of subjects whose wounds reduce in surface area by more than 40% in four weeks
Conditions Studied
Interventions
- DEVICE BlastX with negative pressure therapy
Study Locations (1)
Pennsylvania
- Armstrong County Memorial Hospital - Kittanning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-10-24 |
| Est. Completion | 2022-02-01 |
| Phase | NA |
What the finished NCT04265170 record still lists
NCT04265170 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 30,115-participant average among 10 other Pressure Ulcer trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Pressure Ulcer appearing as the primary indexed condition, and to 1 intervention - of which BlastX with negative pressure therapy is the first listed.
NCT04265170 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04265170 about?
NCT04265170 is a clinical study titled "Evaluating Blast-X® in Combination With Negative Pressure Wound Therapy". A Multi-center, Prospective Clinical Trial Evaluating the Combination of BlastX and Negative Pressure Wound Therapy (VAC).To evaluate the 4-week healing trajectory/wound area reduction with BlastX/VAC as compared with historical pre-study 4-week healing trajectory data and data from the US Wound Reg...
What is the current status of trial NCT04265170?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2019-10-24. Estimated completion is 2022-02-01.
What conditions does trial NCT04265170 study?
This clinical trial studies the following conditions: Pressure Ulcer.
What interventions are being tested in trial NCT04265170?
The interventions under investigation include: BlastX with negative pressure therapy (DEVICE).
Who is sponsoring clinical trial NCT04265170?
This trial is sponsored by SerenaGroup, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04265170 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pressure Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04265170's enrollment target sits among peer trials
20 8th of 10 higher than 3 of 10 other Pressure Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pressure Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Clinical Acceptance of a NPWT Wound Care System
COMPLETED · NA
-
AFT/CLP-LAL RCT Stage 3 or 4 Pressure Injuries
COMPLETED · NA
-
Evaluation Of An Advanced Borderless Dressing
COMPLETED · NA
-
Fluid Immersion Simulation (FIS) System Versus Air Fluidized Bed (AFB) System for Pressure Ulcers
COMPLETED · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
-
Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI